オプティアム・バイオテクノロジーズ株式会社
5 known investors
Optieum develops next-generation CAR-T cell therapies using a proprietary CAR discovery platform to optimize immune cell activation for treating solid tumors and hematological malignancies. The company engineers precision CAR constructs to enhance T-cell therapeutic efficacy.